MS News That Caught My Eye This Week: Ocrevus and Insurance, Intimacy Issues, Breastfeeding
From: Multiple Sclerosis News Today By: Ed Tobias Read more here.
Early Uptake of Roche/Genentech’s Ocrevus Off to Stellar Start, According to Latest Quarterly Update from Spherix Global Insights
The Q2 edition of RealTime Dynamix™: Multiple Sclerosis finds that trial rates for Ocrevus are in-line with pre-launch estimates and robust uptake of the drug is anticipated in the next six months Download Report Overview July 19, 2017 – Exton, PA – For the past year, neurologists have been reporting high anticipation for Roche/Genentech’s Ocrevus […]
Roche’s Ocrevus: Penetrating Beyond Progressive MS
Recent analysis of over 2,000 patient charts indicates Ocrevus will present a challenge to other disease-modifying therapies (DMTs) in the RRMS segment as well as the PPMS segment, according to new data released by Spherix Global Insights. Download Report Overview: Multiple Sclerosis Download Report Overview: DMT New Starts in MS EXTON, Pa., May 12, 2017 […]
RealTime Dynamix™: Multiple Sclerosis US Q2
The Multiple Sclerosis (MS) market is more dynamic and complex than ever with several disease-modifying therapies (DMTs) currently available and a potential game-changer entry, in the form of Roche/Genentech’s Ocrevus (ocrelizumab), approved by the FDA on March 28, 2017. RealTime Dynamix™: Multiple Sclerosis allows marketing professionals to keep abreast and react to these market changes […]
RealWorld Dynamix™: DMT New Starts in Multiple Sclerosis US 2017
The Multiple Sclerosis (MS) market has become fiercely competitive with the introduction of new disease-modifying therapies (DMTs) over the past several years and new therapies, such as Roche’s ocrelizumab, on the horizon. As physicians, patients and industry adapt to these changes, Spherix Global Insights examines the most sought after market, first line new patient starts, […]
Roche Nabs FDA Approval for “Game-changing” Therapy for the Treatment of Multiple Sclerosis
The Q1 edition of RealTime Dynamix™: Multiple Sclerosis published by Spherix Global Insights finds that adoption of Ocrevus will be quick for patients with primary progressive multiple sclerosis, but uptake will be more muted in patients with relapsing forms of the disease Download Report Overview: Multiple Sclerosis Download Report Overview: DMT Switching in MS CAMBRIDGE, […]
RealTime Dynamix™: Multiple Sclerosis Q1
The Multiple Sclerosis (MS) market is more dynamic and complex than ever with several disease-modifying therapies (DMTs) currently available and a potential game-changer entry, in the form of Roche/Genentech’s Ocrevus (ocrelizumab), approved by the FDA on March 28, 2017. RealTime Dynamix™: Multiple Sclerosis allows marketing professionals to keep abreast and react to these market changes […]
Studies of the Multiple Sclerosis (MS) Market Highlight the Increasing Penetration of Oral Disease-modifying Therapies (DMTs) into First Line Position
ZUG, Switzerland, Jan. 17, 2017 /PRNewswire/ — The MS market has shifted over the course of 2016 according to the Q4 update of RealTime Dynamix™, an independent report based on survey responses of 100 US neurologists who actively manage patients with MS. According to the study, oral DMTs captured a significantly higher share at the […]
Roche’s Ocrelizumab Expected To Introduce Major Shifts In The Treatment Paradigm For Multiple Sclerosis.
Spherix Global Insights releases the Q3 update for RealTime Dynamix™: Multiple Sclerosis based on survey responses from 104 US neurologists. Download Report Overview CAMBRIDGE, Mass., Oct. 11, 2016 — There is high anticipation for Roche’s ocrelizumab, a monoclonal antibody that was granted “Breakthrough Therapy Designation” by the FDA earlier this year for its potential indication in […]
Neurologists Report Increasing Payer Pressure for Disease-Modifying Therapies, Resulting in Suboptimal Treatment for Some Patients with Multiple Sclerosis
Download Report Overview August 1, 2016 – Cambridge, MA- In the Q2 update of RealTime Dynamix™: Multiple Sclerosis, roughly one-quarter of the respondents reported increased payer restrictions for Teva’s Copaxone while restrictions have eased somewhat for Sandoz’s Glatopa, Novartis’ Extavia and Biogen’s Tecfidera. While half of the neurologists agreed that payers are becoming more aggressive […]
